YHB Investment Advisors Inc. Has $18.63 Million Stock Position in Danaher Co. (NYSE:DHR)

YHB Investment Advisors Inc. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 0.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,162 shares of the conglomerate’s stock after selling 748 shares during the period. Danaher makes up approximately 1.5% of YHB Investment Advisors Inc.’s investment portfolio, making the stock its 13th largest position. YHB Investment Advisors Inc.’s holdings in Danaher were worth $18,631,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Decker Retirement Planning Inc. acquired a new position in Danaher during the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher during the 3rd quarter worth $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Danaher in the third quarter worth about $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 1.9 %

NYSE DHR opened at $250.51 on Tuesday. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The business has a 50 day moving average price of $235.33 and a 200-day moving average price of $253.62. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $180.94 billion, a price-to-earnings ratio of 47.81, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DHR. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research note on Thursday, October 31st. TD Cowen boosted their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Raymond James reduced their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Stephens reaffirmed an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.